JPMorgan Upgrades Novavax On Potential 'Best-In-Class' COVID Vaccine By: TalkMarkets August 05, 2020 at 09:20 AM EDT JPMorgan analyst Eric Joseph upgraded Novavax to Overweight from Neutral with a price target of $275, up from $105. Read More >> Related Stocks: Novavax Inc